The S&P/ASX 200 Index (ASX: XJO) plummeted by 191.9 points or 2.44% on Friday to finish the week at 7,667.8 points.
Uncertainty about how the newly announced reciprocal US tariffs will impact ASX 200 shares fuelled today's dive.
Based on closing values, today's market rout has pushed the ASX 200 into an official market correction.
A market correction is defined as a major index falling 10% from its most recent peak.
The ASX 200 narrowly avoided a correction last month after it fell 9.43% from its record high on 14 February to a trough on 13 March.
The fall saw several blue-chip shares trading at multi-year lows, including Fortescue Ltd (ASX: FMG) and CSL Ltd (ASX: CSL).
The ASX 200 began a rebound on 14 March, but this week's US tariffs news has brought that undone.
The ASX 200 closed down 10.38% from its 14 February high today.
Today, we heard from more companies about the potential impact of the tariffs on their operations.
Let's take a look.
The Amotiv share price closed 16.72% lower at $7.32 after the auto parts retailer issued a trading update and commented on the US tariffs.
Amotiv said:
In response to these recent tariff announcements, the Group is assessing a range of tactical and strategic actions to manage the risks and realise the opportunities of these changes.
These include re-sourcing of finished goods, re-pricing and use of alternative manufacturing and supply locations.
Mesoblast shares closed 5.87% lower at $1.765.
The ASX 200 biotech company sought to reassure investors today.
In a statement, it said:
Mesoblast allogeneic cell therapy products are designated 'U.S. country of origin' and not subject to U.S. tariffs.
Ansell shares closed 3% higher at $30.22 today.
The company issued a statement saying it would "fully offset the tariff increases through pricing".
Ansell said approximately 43% of its revenue comes from the US.
The majority of products sold in the US are imported from Malaysia, Sri Lanka, Thailand, Vietnam, and China.
The company said:
Ansell plans to fully offset the tariff increases through pricing, and we have had conversations with customers to this effect including in the past 24 hours.
It is worth noting that the vast majority of manufacturing in our industry is conducted in Asian countries now subject to US tariffs, and US industry manufacturing capacity for comparable hand and body protection products is negligible.
Longer term, Ansell retains the flexibility to respond to changes in the relative attractiveness of traditional PPE manufacturing locations through 14 owned manufacturing plants in 9 countries and our extensive partner network.
The ASX 200 consumer discretionary stock closed 12.01% lower at $26.44 on Friday, compounding a 5% decline on Thursday.
Breville issued a statement on the US tariffs yesterday:
Subject to the current uncertainty and fluidity in the economic environment, US tariff implementation and iteration, coupled with any country-specific responses, it is likely that the Group's input costs will increase for FY26.
The Group will continue to make tactical adjustments, where appropriate, to lessen the potential short-term impacts from any new tariffs.
The CSL share price closed 1.7% lower at $253.30.
In a statement, the ASX 200 healthcare giant said:
At this stage pharmaceutical products are not subject to the reciprocal tariffs.
CSL is continuing to assess the broader impact of the tariffs and will monitor further announcements by the U.S. Government.
You can check out a complete reciprocal US tariffs list by country here.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.